Christ Hospital Performs First U.S. Robotic Mitral Valve Replacement
The investigational Capstan Compass system was used in an FDA-authorized early feasibility study in Cincinnati.
Updated on Nov. 22, 2026 in Diseases

The Christ Hospital Health Network performed the first U.S. procedure using an investigational robotic system for mitral valve replacement on November 9. The procedure was part of a Food and Drug Administration-authorized early feasibility study.
Why it matters
The robotic platform is designed to improve catheter stability and control, with the aim of more precise implant placement during heart valve replacement. The system remains investigational and is not approved for commercial use in the United States.
The procedure is the first U.S. use of the Capstan Compass system, following earlier robotic mitral valve procedures performed by Capstan Medical in Chile in 2025. No patient condition or outcome data has been released, and the system is not yet approved for commercial use.
The players
The Christ Hospital Health Network
A Cincinnati-based health system with a regional network of hospitals and specialty cardiac programs.
Capstan Medical
A medical device company that develops robotic catheter-based systems for minimally invasive heart valve procedures.
Dr. Santiago Garcia
A cardiologist who directs The Christ Hospital's Structural Heart Program and led the procedure.
The details
Doctors control a flexible catheter and position the valve implant using a handheld controller, with robotic navigation guiding the system. The team was led by Dr. Santiago Garcia, director of The Christ Hospital's Structural Heart Program, and Capstan Medical developed the Capstan Compass system.
Timeline
November 9, 2026: First U.S. robotic mitral valve replacement performed at The Christ Hospital in Cincinnati.
2025: Capstan Medical performed robotic mitral valve procedures in Chile.
Heart Valve Technology
The procedure extends Capstan Medical's earlier robotic mitral valve work in Chile into the U.S. under an FDA early feasibility study. It marks a step toward robotic, catheter-based valve replacement as an alternative to open-heart surgery, though the system is not yet commercially available.
Patients with mitral valve disease may eventually have a less invasive option than open-heart surgery if robotic catheter systems receive regulatory approval. For now, the Capstan Compass system is available only through clinical studies and is not a standard treatment option.
The takeaway
Robotic catheter systems could eventually make heart valve replacement less invasive, but this procedure is an early research milestone rather than a new standard of care. Readers with valve concerns should discuss options with their cardiologist.
Further reading
For more on the condition this procedure treats, see Heart Disease coverage in Cincinnati.
Source note: This article includes information reported by WKRC.






